Phase 1 Depression Clinical Trials
59 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 59 trials
Recruiting
Phase 1
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
DepressionHealthy VolunteerMajor Depressive Disorder
National Institute of Mental Health (NIMH)150 enrolled1 locationNCT03065335
Recruiting
Phase 1
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
DepressionMajor Depressive DisorderMajor Depression
National Institute of Mental Health (NIMH)70 enrolled1 locationNCT03973268
Recruiting
Phase 1
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
DepressionMajor Depression Disorder
Deepak C. D'Souza60 enrolled1 locationNCT06671977
Recruiting
Phase 1
DBS for Depression
Treatment Resistant Depression
Northwell Health20 enrolled1 locationNCT06096207
Recruiting
Phase 1
Pharmacologic Augmentation of TMS for Depression With D-serine
Depression
Mclean Hospital60 enrolled1 locationNCT06876129
Recruiting
Phase 1
ACT for Individuals With MNCD and Their Care Partners
Depression in AdultsAnxiety Disorder GeneralizedGrief
Texas Tech University100 enrolled1 locationNCT07239609
Recruiting
Phase 1
ENA-001 for Opioid Induced Respiratory Depression
Respiratory Depression
Enalare Therapeutics Inc.36 enrolled3 locationsNCT06967259
Recruiting
Phase 1Phase 2
Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease
Quality of LifeDepression, AnxietyStress Reaction+1 more
Children's Hospital Los Angeles66 enrolled1 locationNCT05685368
Recruiting
Phase 1Phase 2
Personalized Ultrasonic Brain Stimulation for Depression (R61)
Depression - Major Depressive DisorderMajor Depressive EpisodeTreatment-Resistant Major Depressive Disorder
Brian Mickey30 enrolled1 locationNCT06902298
Recruiting
Phase 1Phase 2
Modulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains
Depression - Major Depressive Disorder
University of Cincinnati67 enrolled1 locationNCT06795451
Recruiting
Phase 1Phase 2
Psilocybin to Treat Depression in Spinal Cord Injury
Depression - Major Depressive DisorderSpinal Cord InjuryVeteran
James J. Peters Veterans Affairs Medical Center30 enrolled1 locationNCT07251491
Recruiting
Phase 1
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET
Depression
National Institute of Mental Health (NIMH)108 enrolled1 locationNCT05703685
Recruiting
Phase 1
Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department
DepressionSuicideSuicidal Ideation
Lindsay Maguire, MD50 enrolled2 locationsNCT06085937
Recruiting
Phase 1
Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery
PainPostpartum Depression
Grace Lim, MD, MS50 enrolled2 locationsNCT06767566
Recruiting
Phase 1
Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects
Depression - Major Depressive DisorderAnhedonia
Medical University of Vienna85 enrolled1 locationNCT07490353
Recruiting
Phase 1
Psilocybin for Treatment-Resistant Depression in Autism
Autism Spectrum DisorderTreatment Resistant Depression
Centre for Addiction and Mental Health20 enrolled1 locationNCT06731621
Recruiting
Phase 1
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
Depression
National Institute of Mental Health (NIMH)64 enrolled1 locationNCT04582916
Recruiting
Phase 1
Open-Label Psilocybin Study in Transdiagnostic Population
AnxietyDepression - Major Depressive DisorderPTSD+5 more
Yale University50 enrolled1 locationNCT06442423
Recruiting
Phase 1
A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression
DepressionHealthyMajor Depressive Disorder
Sirtsei Pharmaceuticals, Inc.36 enrolled2 locationsNCT06570369
Recruiting
Phase 1
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
HealthyMajor Depressive DisorderTreatment Resistant Depression
Baylor College of Medicine100 enrolled2 locationsNCT06480201